Navigation Links
Breast cancer: DMP is largely consistent with guidelines
Date:7/16/2014

On 16 July 2014 the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with breast cancer. The aim of the report is to identify those recommendations from current guidelines of high methodological quality that may be relevant for the planned revision of the disease management programme (DMP). According to the results of the report, there is no compelling need for revision of any part of the DMP. However, IQWiG identified some aspects that could be supplemented and specified.

DMPs are revised regularly

After being commissioned by the Federal Joint Committee (G-BA), IQWiG systematically searched for new guidelines, assessed their methodological quality, and extracted relevant recommendations from these guidelines. In a next step these recommendations were compared with the specifications for the German DMP.

A need for revision may arise if new studies provide new evidence on a disease and its treatment. It is therefore legally specified that a DMP must be revised at regular intervals. It is the Institute's responsibility to firstly identify differences between the guideline recommendations and the DMP. It is then the G-BA'sresponsibility to examine whether these differences should actually lead to a revision of the DMP.

26 relevant guidelines identified

IQWiG was able to include a total of 26 guidelines in its investigation. Six of these guidelines comprehensively address the care of patients with breast cancer. Seven guidelines exclusively deal with early breast cancer, four further guidelines with advanced breast cancer (stage IV). The remaining nine guidelines address specific aspects such as radiotherapy, breast reconstruction or adjuvant systematic treatment.

Supplementations desirable

As IQWiG determined, there are several health-care aspects for which the recommendations of the DMP should be revised. Among other aspects, this applies to diagnostics and measures in primary therapy: The guidelines address the performance of a magnetic resonance imaging (MRI) scan in specific therapeutic indications, explicitly advising against routine MRI scans. With regard to radiotherapy for breast cancer, the guidelines provide recommendations on hypofractionated radiotherapy an aspect currently not considered by the DMP.

Process of report production

IQWiG published the preliminary results in the form of the preliminary report in November 2013 and interested parties were invited to submit comments. At the end of the commenting procedure, the preliminary report was revised and sent as a final report to the commissioning agency in May 2014. The written comments submitted are published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.


'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. New skin gel fights breast cancer without blood clot risk
2. Praeclarus Press Announces The Release of Three New Breastfeeding Support Books For International Lactation Consultant Association's Annual Conference, July 22-25, 2014
3. Florida Breast Cancer Foundation funds UM study of stress management in breast cancer treatment
4. Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com
5. Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers
6. USC stem cell researcher targets the seeds of breast cancer metastasis
7. Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells
8. Protein pushes breast cancer cells to metastasize
9. Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses
10. Association found between high cholesterol and breast cancer
11. New test predicts the risk of non-hereditary breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... MALO, FRANCE (PRWEB) , ... January 21, 2017 , ... ... of the Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER ... East Africa, Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to ...
(Date:1/21/2017)... ... 2017 , ... The Nobel Biocare™ dental implant company is ... its creos™ line of bone regenerative products. Specifically, the Nobel Biocare™ ... creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In addition ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Doctor C ... it attended the January ECRM trade show to continue the marketing and distribution of ... C supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. ...
(Date:1/20/2017)... ... , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in ... has been life-saving as she has been on the trial for more than ... with ovarian cancer in 2009. She underwent standard chemotherapy but a year later went ...
(Date:1/20/2017)... ... , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on to ... published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, ... years of age, he joined the Navy and got married right out of boot camp. ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast ... ... Sales Volume, Company Analysis and Forecast to 2022 provides a ... The growing prevalence of hearing impairment coupled with an ...
(Date:1/20/2017)... -- Stock-Callers.com today evaluates the following Drug Manufacturers ... Nordisk A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. ... (NASDAQ: PTX ). These stocks belong to the ... 2017, finishing near its session lows. As per a NASDAQ ... shares of health care companies in the S&P 500 also ...
Breaking Medicine Technology: